Table 2 Quality of Care Process Measures for Medicaid-Enrolled Youth with Mental Health and Substance Abuse Disorders Measure Description Developer Evidence Ratinga Polypharmacy > 4 medications % of enrollees 18 years of age or younger on four (4) or more PSYCKES/TEXAS C psychotropic medications for 60 days during the measurement year ≥ > 2 antipsychotics % of children 18 years of age or younger who are on two (2) or more PSYCKES/TEXAS/ B antipsychotic medications for 60 days concomitantly during the MMDLN/Rutgers CERTS ≥ measurement year > 3 mood stabilizers % or children 18 years of age or younger who are on three (3) or more SYKES/TEXAS C concomitant mood stabilizing agents for 60 days during the ≥ measurement year > 2 stimulants % of enrollees 18 years of age or younger who are on two (2) or more PSYCKES/TEXAS C concomitant amphetamine and methylphenidate-based stimulants for ≥ 60 days during the measurement year Dosing and Duration Chronic use of benzodiazepine % of enrollees 18 years of age or younger with a mental health diagnosis Research B who used benzodiazepines for 60 days or more ≥ Higher than recommended dose of % or enrollees 18 years of age or younger who are prescribed a dose of PSYCKES A antipsychotic medications antipsychotic medication that exceeds the recommended maximum during the measurement period Higher than recommended dose of % of enrollees 18 years of age or younger on ADHD medications with PSYCKES B ADHD medications evidence of a dose higher than the recommended maximum during the measurement period Depressive Disorders Antidepressant medication % of members 18 years of age and younger diagnosed with a new NCQA/HEDIS/AHRQ A management, acute phase episode of depression and treated with antidepressant medication who remained on an antidepressant drug during the 84-day (12 week) acute treatment phase
Table 2 Quality of Care Process Measures for Medicaid-Enrolled Youth with Mental Health and Substance Abuse Disorders Measure Description Developer Evidence Ratinga Polypharmacy > 4 medications > 2 antipsychotics > 3 mood stabilizers > 2 stimulants % of enrollees 18 years of age or younger on four (4) or more psychotropic medications for ≥ 60 days during the measurement year % of children 18 years of age or younger who are on two (2) or more antipsychotic medications for ≥ 60 days concomitantly during the measurement year % or children 18 years of age or younger who are on three (3) or more concomitant mood stabilizing agents for ≥ 60 days during the measurement year % of enrollees 18 years of age or younger who are on two (2) or more concomitant amphetamine and methylphenidate-based stimulants for ≥ 60 days during the measurement year PSYCKES/TEXAS PSYCKES/TEXAS/ MMDLN/Rutgers CERTS SYKES/TEXAS PSYCKES/TEXAS C B C C Dosing and Duration Chronic use of benzodiazepine Higher than recommended dose of antipsychotic medications Higher than recommended dose of ADHD medications % of enrollees 18 years of age or younger with a mental health diagnosis who used benzodiazepines for ≥ 60 days or more % or enrollees 18 years of age or younger who are prescribed a dose of antipsychotic medication that exceeds the recommended maximum during the measurement period % of enrollees 18 years of age or younger on ADHD medications with evidence of a dose higher than the recommended maximum during the measurement period Research PSYCKES PSYCKES B A B Depressive Disorders Antidepressant medication management, acute phase % of members 18 years of age and younger diagnosed with a new episode of depression and treated with antidepressant medication who remained on an antidepressant drug during the 84-day (12 week) acute treatment phase NCQA/HEDIS/AHRQ A
QualityMeasures.docx